BioAge Labs, Inc. (BIOA)
NASDAQ: BIOA · Real-Time Price · USD
20.77
+0.78 (3.90%)
At close: Jun 18, 2026, 4:00 PM EDT
20.18
-0.59 (-2.84%)
After-hours: Jun 18, 2026, 6:56 PM EDT
BioAge Labs Employees
As of December 31, 2025, BioAge Labs had 62 total employees, including 60 full-time and 2 part-time employees. The number of employees decreased by 2 or -3.13% compared to the previous year.
Employees
62
Change (1Y)
-2
Growth (1Y)
-3.13%
Revenue / Employee
$166,387
Profits / Employee
-$1,450,484
Market Cap
923.28M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Dec 31, 2025 | 62 | -2 | -3.13% | 60 | 2 |
| Dec 31, 2024 | 64 | 8 | 14.29% | 62 | 2 |
| Jun 30, 2024 | 60 | - | - | 58 | 2 |
| Mar 31, 2024 | 56 | - | - | 54 | 2 |
| Dec 31, 2023 | 56 | - | - | 54 | 2 |
Related Stocks
| Company Name | Employees |
|---|---|
| Perrigo Company | 8,100 |
| Evotec SE | 4,526 |
| Phibro Animal Health | 2,475 |
| Amphastar Pharmaceuticals | 1,976 |
| Alvotech | 1,279 |
| Pacira BioSciences | 829 |
| Cronos Group | 610 |
| Xeris Biopharma Holdings | 435 |
BIOA News
- 3 days ago - BioAge Labs doses first participant in QUELL-CV trial of BGE-102 - TheFly
- 3 days ago - BioAge Labs Announces First Participant Dosed in QUELL-CV, a Phase 2 Proof-of-Concept Trial of BGE-102, a Novel Oral NLRP3 Inhibitor, in Patients at Elevated Cardiovascular Risk - GlobeNewsWire
- 11 days ago - BioAge Labs Transcript: Goldman Sachs 47th Annual Global Healthcare Conference 2026 - Transcripts
- 15 days ago - BioAge Labs Transcript: Jefferies Global Healthcare Conference 2026 - Transcripts
- 23 days ago - BioAge Labs initiated with a Buy at Roth Capital - TheFly
- 4 weeks ago - BioAge Labs to Present at Upcoming Investor Conferences - GlobeNewsWire
- 5 weeks ago - BioAge Labs initiated with a Buy at BTIG - TheFly
- 6 weeks ago - BioAge Labs Transcript: R&D Day 2026 - Transcripts